Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ProteoNic and OET Sign UNic™ License for Use in flashBAC™

Published: Friday, March 08, 2013
Last Updated: Friday, March 08, 2013
Bookmark and Share
Both companies will be represented at BIO Europe Spring in Barcelona on March 11 -13.

ProteoNic BV and Oxford Expression Technologies Ltd (OET) have extended their partnership by signing a commercial license agreement.

OET obtains the right to use ProteoNic’s UNic™ translation enhancing elements in its flashBAC™ system for third party recombinant protein production services.

ProteoNic will provide technical support. Financial terms include upfront and royalty payments.

Both companies will be represented at BIO Europe Spring in Barcelona on March 11 -13 and are available for partnering meetings.

Under a previous collaboration, the two companies have successfully combined ProteoNic’s award-winning UNic™ translation enhancing technology with OET’s flashBAC™ system to significantly enhance recombinant protein yields in insect cells.

Application of UNic™ not only allows increased overall efficiency and reduction of costs, but also facilitates (pre)clinical development of biopharmaceutical products that otherwise might be discarded due to difficulties in achieving acceptable production levels.

This allows biopharmaceutical companies to broaden their pipeline and increase its value while reducing the drug development risk profile. From now on OET’s contract manufacturing services will include UNic™ technology.

Rory Woodhouse, Sales Manager at OET commented: “The combination of the unique UNic™ technology and the flashBAC™ expression system has already proved itself to have a positive effect on eukaryotic protein expression. This new agreement will enable us to build on our partnership and experience with ProteoNic, working together to provide a superior platform for our customers with more challenging to express proteins.”

Victor Schut, Chief Business Officer at ProteoNic added: “We are pleased to have demonstrated the value of partnership in combining two proven technologies. This will allow our customers to benefit from both our expertise through only one service. The successful application of our technology in the flashBAC system adds another recombinant protein production platform to our portfolio enabling us to serve a new market for ProteoNic.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ProteoNic Announces Closing of Financing Round
Completion of a € 6 mln equity financing round led by US-based Fairbanks Investment Fund.
Monday, October 03, 2011
ProteoNic and OET Join Forces Combining UNic™ with flashBAC™ Protein Expression Platform
Companies combine ProteoNic’s award winning UNic™ translation enhancement technology with OET’s flashBAC™ system to enhance protein yields.
Thursday, March 10, 2011
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!